Table 3.
Variables associated with the risks of death and recurrence in invasive ductal carcinoma (n=266)
| Variable | Univariable analysis* | Multivariable analysis* | ||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Overall survival | ||||
| DUSP4 expression (negative vs. positive) | 0.955 (0.373-2.444) | 0.924 | 0.600 (0.200-1.803) | 0.363 |
| AJCC stage (I, II vs. III, IV) | 2.836 (1.230-6.543) | 0.015 | 1.448 (0.490-4.277) | 0.503 |
| Lymphatic invasion (absent vs. present) | 2.499 (0.978-6.386) | 0.056 | 1.604 (0.465-5.528) | 0.454 |
| Perinodal tumor extension (absent vs. present) | 2.957 (1.204-7.264) | 0.018 | 3.329 (1.105-10.030) | 0.033 |
| ER/PR status (all negative vs. one or both positive) | 0.266 (0.107-0.658) | 0.004 | 0.280 (0.080-0.981) | 0.047 |
| Triple negativity (triple negative vs. not) | 0.305 (0.126-0.735) | 0.008 | 0.624 (0.191-2.039) | 0.435 |
| Disease-free survival | ||||
| DUSP4 expression (negative vs. positive) | 1.434 (0.778-2.644) | 0.248 | 1.164 (0.587-2.311) | 0.663 |
| AJCC stage (I, II vs. III, IV) | 3.124 (1.741-5.606) | < 0.001 | 1.286 (0.612-2.702) | 0.508 |
| Lymphatic invasion (absent vs. present) | 3.531 (1.748-7.133) | < 0.001 | 2.551 (1.035-6.287) | 0.042 |
| Perinodal tumor extension (absent vs. present) | 3.813 (2.070-7.023) | < 0.001 | 3.030 (1.380-6.649) | 0.006 |
| ER/PR status (all negative vs. one or both positive) | 0.462 (0.252-0.846) | 0.012 | 0.552 (0.214-1.420) | 0.218 |
| Triple negativity (triple negative vs. not) | 0.448 (0.234-0.859) | 0.016 | 0.563 (0.215-1.469) | 0.240 |
HR=hazard ratio; CI=confidence interval; DUSP4=dual-specificity protein phosphatase 4; AJCC=American Joint Committee on Cancer; ER=estrogen receptor; PR=progesterone receptor.
*Cox proportional hazards model.